MedPath
EMA Approval

Tolura

C09CA07

telmisartan

Angiotensin II antagonists, plain

telmisartan

Hypertension

Basic Information

C09CA07

telmisartan

Angiotensin II antagonists, plain

Therapeutic indication

Hypertension

Treatment of essential hypertension in adults.

Cardiovascular prevention

Reduction of cardiovascular morbidity in patients with:

  • manifest atherothrombotic cardiovascular disease (history of coronary heart disease or peripheral arterial disease) or;
  • type 2 diabetes mellitus with documented target organ damage.

Overview Summary

This is a summary of the European public assessment report (EPAR) for Tolura. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tolura.

Authorisations (1)

EMEA/H/C/001196

Krka, d.d., Novo mesto,Krka, d.d., Novo mesto,Šmarješka cesta 6,8501 Novo mesto,Slovenia

Authorised

June 4, 2010

Active Substances (2)

Telmisartan

Telmisartan

Documents (11)

Tolura : EPAR - Public assessment report

June 21, 2010

INITIAL_MARKETING_AUTHORISATION_DOCUMENTS

Tolura : EPAR - Procedural steps taken and scientific information after authorisation

July 20, 2011

CHANGES_SINCE_INITIAL_AUTHORISATION

CHMP positive summary of opinion for Tolura

March 18, 2010

INITIAL_MARKETING_AUTHORISATION_DOCUMENTS

Tolura : EPAR - All Authorised presentations

June 21, 2010

AUTHORISED_PRESENTATIONS

Tolura : EPAR - Procedural steps taken and scientific information after authorisation

March 19, 2025

CHANGES_SINCE_INITIAL_AUTHORISATION

Tolura : EPAR - Public assessment report

June 21, 2010

CHANGES_SINCE_INITIAL_AUTHORISATION

Tolura : EPAR - Summary for the public

June 21, 2010

OVERVIEW_DOCUMENT

Tolura-H-C-1196-A31-0013 : EPAR - Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommenda...

September 25, 2014

CHANGES_SINCE_INITIAL_AUTHORISATION

Tolura : EPAR - Product Information

June 21, 2010

DRUG_PRODUCT_INFORMATION

Tolura : EPAR - Procedural steps taken and scientific information after authorisation (archive)

July 20, 2011

CHANGES_SINCE_INITIAL_AUTHORISATION

CHMP positive summary of opinion for Tolura

March 18, 2010

CHANGES_SINCE_INITIAL_AUTHORISATION

Overview Q&A (8)

Question

How is Tolura used?

Answer

For the treatment of essential hypertension, the recommended dose of Tolura is 40 mg once a day, but some patients may benefit from using a 20-mg dose. If the target blood pressure is not reached, the dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide.

For the prevention of cardiovascular problems, the recommended dose is 80 mg once a day. The doctor should monitor the patient’s blood pressure closely when starting Tolura, and may decide to adjust the patient’s blood pressure-lowering medication.

Question

How does Tolura work?

Answer

The active substance in Tolura, telmisartan, is an ‘angiotensin II receptor antagonist’, which means that it blocks the action of a hormone in the body called angiotensin II. Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the receptors to which angiotensin II normally attaches, telmisartan stops the hormone having an effect, allowing the blood vessels to widen. This allows the blood pressure to drop, reducing the risks associated with high blood pressure, such as having a heart attack. It also allows the heart to pump blood more easily, which can help to reduce the risk of future cardiovascular problems.

Question

Other information about Tolura

Answer

The European Commission granted a marketing authorisation valid throughout the EU for Tolura to Krka, d.d., Novo mesto on 4 June 2010. The marketing authorisation is valid for five years, after which it can be renewed.

For more information about treatment with Tolura, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Question

Why has Tolura been approved?

Answer

The CHMP concluded that, in accordance with EU requirements, Tolura has been shown to have comparable quality and to be bioequivalent to Micardis. Therefore, the CHMP’s view was that, as for Micardis, the benefit outweighs the identified risk. The Committee recommended that Tolura be given marketing authorisation.

Question

What is Tolura?

Answer

Tolura is a medicine that contains the active substance telmisartan. It is available as white tablets (round: 20 mg; oval: 40 mg; capsule-shaped: 80 mg).

Tolura is a ‘generic medicine’. This means that Tolura is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Micardis.

Question

What is Tolura used for?

Answer

Tolura is used to treat essential hypertension (high blood pressure) in adults. ‘Essential’ means that the hypertension has no obvious cause.

Tolura is also used to prevent cardiovascular problems (problems with the heart and blood vessels) such as heart attacks. It is used in patients who have had problems due to blood clots in the past (such as heart disease or artery disease) or who have type 2 diabetes that has damaged an organ (such as the eyes, heart or kidneys).

The medicine can only be obtained with a prescription.

Question

How has Tolura been studied?

Answer

Because Tolura is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Micardis. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

Question

What are the benefit and risk of Tolura?

Answer

Because Tolura is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine’s.

© Copyright 2025. All Rights Reserved by MedPath